Welcome to our dedicated page for Merit Med Sys SEC filings (Ticker: MMSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how FDA approvals, product recalls, and R&D outlays sway Merit Medical Systems’ valuation can feel like surgery without anesthesia. The company’s annual report alone tops 250 pages, and every quarter another detailed 10-Q arrives with fresh data on catheter sales, embolization demand, and global logistics costs. If you’ve ever searched “Where can I find Merit Medical’s quarterly earnings report 10-Q filing?” or tried to decode footnotes on segment revenue, Stock Titan offers a precise remedy: AI-powered summaries that translate dense disclosures into plain language.
Our engine ingests each EDGAR submission the moment it posts—10-K, 10-Q, 8-K, Form 4, and the proxy—and converts them into actionable insights. Need “Merit Medical insider trading Form 4 transactions” before the bell? Real-time alerts flag every executive stock move. Curious about how warranty reserves changed after a material event? The platform’s AI links the note inside the filing and highlights the numbers. From high-level dashboards to paragraph-by-paragraph explanations, Stock Titan saves hours while keeping context intact.
Everything investors typically look for is one click away:
- “Merit Medical Form 4 insider transactions real-time” with historical charts
- “Merit Medical annual report 10-K simplified” sections on FDA risk and competitive landscape
- “Merit Medical proxy statement executive compensation” tables parsed into easy comparisons
- “Merit Medical 8-K material events explained” within minutes of release
- “Merit Medical earnings report filing analysis” that benchmarks quarter-over-quarter growth
- Guidance for understanding Merit Medical SEC documents with AI
Whether you monitor “Merit Medical executive stock transactions Form 4” ahead of product launches or study supply-chain commentary inside the 10-K, Stock Titan delivers complete coverage, AI clarity, and real-time speed.
Merit Medical Systems insider transactions: The company's President and CEO, Fred P. Lampropoulos, reported multiple stock option exercises and share surrenders on 08/29/2025. He exercised 159,151 options at a $55.73 exercise price and an additional 2,000 options at $55.73, resulting in 159,151 and 2,000 underlying shares respectively that were reported as acquired. He also surrendered 124,824 shares (for payroll taxes and option payment) and his spouse surrendered 1,454 shares for the same purpose; neither surrender involved open-market sales. Post-transactions, Mr. Lampropoulos beneficially owned 1,204,779 shares directly and certain additional shares indirectly through spouse and 401(k) holdings. Several outstanding option grants with various exercise prices and vesting schedules remain.
Lynne N. Ward, a director of Merit Medical Systems, Inc. (MMSI), executed option exercises and share sales on 08/22/2025. She exercised 3,000 non-qualified stock options with a $34.46 exercise price, resulting in 3,000 shares acquired. The same day she sold 3,000 shares in multiple transactions at a weighted average price of $88.56. After these transactions she beneficially owned 12,809 shares. The exercised options were originally granted with a $34.46 strike and become exercisable in equal annual installments of 33% commencing 08/28/2020; the exercised tranche had an expiration date of 08/28/2026.
Merit Medical Systems, Inc. (MMSI) Form 144 notice reports a proposed sale of 3,000 common shares valued at $265,683 to be sold through Morgan Stanley Smith Barney on NASDAQ on 08/22/2025. The filing states these shares were acquired the same day via stock option exercise and paid for in cash. The filer represents no undisclosed material adverse information about the issuer. The filing also lists a prior sale by Lynne Ward of 2,433 shares on 08/11/2025 for $206,535.91. Outstanding shares are listed as 59,219,117.
Lynne N. Ward, a director of Merit Medical Systems (MMSI), reported transactions dated 08/11/2025 on a Form 4. The filing shows the exercise of non-qualified stock options with an exercise price of $34.46 and an associated acquisition of 2,433 shares, and a contemporaneous sale of 2,433 shares at $84.8894.
Following the reported activity the form lists non-derivative beneficial ownership figures of 15,242 and 12,809 shares (as reported on separate lines) and indicates 3,000 derivative securities beneficially owned after the transactions, with 5,433 underlying common shares referenced for the options. The form is signed by an attorney-in-fact on 08/12/2025.
Merit Medical Systems (MMSI) submitted a Form 144 reporting a proposed sale of 2,433 common shares, with an aggregate market value of $206,535.91. The shares are listed on NASDAQ and the filing shows 59,219,117 shares outstanding for the issuer, indicating the position sold is a very small fraction of the company’s total shares. The securities were acquired and are being sold on 08/11/2025 as a result of a stock option exercise, and payment was in cash. The sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services at 1 New York Plaza, New York.
The filing indicates Nothing to Report for securities sold in the past three months. The provided content does not identify the named seller or filer CIK in the visible text. The notice includes the standard attestation that the seller does not possess undisclosed material adverse information.
FAQ
What is the current stock price of Merit Med Sys (MMSI)?
What is the market cap of Merit Med Sys (MMSI)?
